Premium
Effect of KCD‐232, a new hypolipidemic agent, on serum lipoprotein changes in hepatoma‐bearing rats
Author(s) -
Irikura T.,
Takagi K.,
Okada K.,
Yagasaki K.
Publication year - 1985
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02534232
Subject(s) - very low density lipoprotein , lipidology , chemistry , clinical chemistry , lipoprotein , medicine , endocrinology , low density lipoprotein , cholesterol , high density lipoprotein , fraction (chemistry) , intermediate density lipoprotein , biochemistry , chromatography
Changes in serum lipoprotein profiles were characterized in Donryu rats subcutaneously implanted with an ascites hepatoma line of AH109A cells and the effect of a new hypolipidemic agent with a structure of 4‐(4′‐chlorobenzyloxy)benzyl nicotinate (KCD‐232) was estimated. With the growth of hepatoma for periods of up to three weeks, a striking decrease in the high density lipoprotein (HDL) fraction and an enormous increase in the VLDL+LDL (very low density lipoprotein+low density lipoprotein) fraction were found in hepatoma‐bearing rats when either precipitation method or electrophoresis was used. These lipoprotein profiles were not influenced by sex. Judging from the electrophoretogram, the increase in VLDL+LDL fraction was due mainly to an increase in LDL fraction. The oral administration of KCD‐232 significantly suppressed the hepatoma‐induced increase in VLDL+LDL with little or no influence on the hepatoma‐induced decrease in HDL. There existed a positive correlation between the hepatoma weight and (VLDL+LDL)‐cholesterol concentration and a negative one between hepatoma and HDL‐cholesterol.